Af 400 (Fluconazole) is an antifungal agent generally used across domains where additional symptomatic support is needed for fungal and yeast infections. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, and may provide support that helps ease the overall symptom load. This medication is commonly used to help with a wide array of fungal conditions.

The therapeutic benefit generally supports the management of conditions marked by increased physiological stress, like candidemia and cryptococcal meningitis, and is relevant for easing recurrent mucosal conditions such as oral thrush and complicated vaginal candidiasis. The medicine is also applied when appropriate in clinical settings to assist with infection risk in immunocompromised patients during periods of high physiological stress. The systemic approach contributes to maintaining stability, particularly when symptoms are more noticeable, and helps address symptom clusters that interfere with daily functioning.

---

Quick Fact: Supports Relief from Localized Discomfort

Af 400 is commonly used across conditions presenting with inflammatory or irritative processes, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Af 400?

Af 400 (Fluconazole) eligibility is strictly defined by regulatory authorities across several population domains.

Use is contraindicated for patients with a known hypersensitivity to fluconazole, related azole antifungals, or any of the product's inactive ingredients. It is also prohibited for patients receiving specific medications known to prolong the QT interval, such as pimozide or quinidine.

Regarding age, the medicine is approved for use in adults and children six months of age and older. Specific physician-determined dosing is required for term newborn infants (0 to 27 days). Safety and efficacy are not established for treating genital candidiasis in individuals under 16 years.

Certain condition-specific restrictions apply. Patients with renal impairment (kidney disease) must receive a mandatory dose adjustment for multiple-dose therapy. Use is permitted only with caution in patients with known hepatic impairment (liver dysfunction) or pre-existing cardiac conditions. High-dose or prolonged use during pregnancy is contraindicated except for life-threatening infections, and it is not recommended during lactation for mothers on repeated doses.

Af 400 Interactions with other medicines and products

Interaction Scope

Medicinal Product Categories
Drugs with a risk of QT prolongation (e.g., specific antiarrhythmics, cisapride, pimozide)
Drugs metabolized by CYP450 Enzymes (particularly CYP2C9, CYP2C19, and CYP3A4 substrates)
Anticoagulants (e.g., warfarin); Statins (HMG-CoA Reductase Inhibitors); Oral Hypoglycemics

Official Interaction Statements

• Contraindicated Combinations: Co-administration with agents known to prolong the QT interval, such as pimozide, cisapride, and quinidine, is strictly contraindicated by regulatory bodies due to the high risk of life-threatening cardiac arrhythmias, including Torsades de Pointes.
• Enzyme-Based Restrictions: As a metabolic inhibitor, Af 400 increases the plasma concentration of numerous co-administered medicines, including anti-epileptics (e.g., phenytoin), immunosuppressants (e.g., cyclosporine, tacrolimus), and certain cancer therapies.
• Anticoagulation Constraints: The prothrombin time may be significantly increased in subjects receiving coumarin-type anticoagulants (e.g., warfarin), requiring close monitoring of international normalized ratio (INR) and potential dose reduction of the anticoagulant.
• Hypoglycemic Agents: Concomitant use with specific sulfonylurea oral hypoglycemics (e.g., glipizide) may result in elevated blood levels of the latter, necessitating careful glucose monitoring.

Connection to the Overall Interaction Profile

The regulatory labeling defines the interaction profile of Af 400 primarily through its inhibition of hepatic cytochrome P450 enzymes, which governs the restrictions on combining it with other medicines. The most significant constraint involves avoiding drugs that carry a risk of serious cardiac dysrhythmias, while other interactions require specific monitoring procedures to manage the increased exposure and potential toxicity of co-administered agents.

Selective Inhibition of Fungal Ergosterol Production

Af 400 (Fluconazole) acts within the domain of enzyme-mediated signaling by selectively targeting and inhibiting lanosterol 14-alpha-demethylase (CYP51), an enzyme exclusive to fungal metabolism. This molecular interaction initiates a cascade that prevents the formation of ergosterol, the required lipid component for the structural integrity and function of the fungal cell membrane.

---

Cellular Damage and Fungistatic Pressure

The inhibition of ergosterol synthesis leads to a dual physiological consequence: depletion of a core structural component and the accumulation of toxic intermediate sterols within the fungal cell. This disruption to the membrane's fluidity and permeability establishes fungistatic pressure, which halts the organism's growth and ability to replicate. This regulated cessation of proliferation is the key physiological adjustment that allows host defense mechanisms to clear the compromised cells.

Af 400 (Fluconazole) is formally approved for administration via the oral route (tablet or suspension) or intravenously as an injection solution. The administered dose is the same regardless of the chosen route due to the drug's high oral bioavailability. For multi-day treatment regimens, official guidelines specify the use of a loading dose on the first day, typically double the maintenance dose, to rapidly achieve steady-state plasma concentrations.

The dosing frequency for maintenance is predominantly once daily, though regimens range from a single 150 mg oral dose for acute conditions to once-weekly schedules for certain types of suppressive therapy. The total duration of use is highly variable, extending from a single day to indefinite therapy for specific chronic conditions. Adult daily maintenance doses officially range from 50 mg to 400 mg.

Regarding administration context, the tablet may be taken with or without food. For consistent systemic drug levels, taking the dose at the same time each day is the procedural standard. A mandatory adjustment to the dosing regimen is required for adult patients with documented renal impairment. The dose must be reduced by 50% when creatinine clearance is less than or equal to 50 mL/min. Pediatric dosing is calculated based on the patient's body weight. IV administration must be performed slowly via infusion, and the oral suspension must be shaken thoroughly before measuring.

Af 400: Recent Clinical Evidence

Research has explored whether the fixed-dose combination of Compound A and Compound B was associated with certain findings in patients managing Condition X. The majority of published research consists of high-quality, randomized, double-blind, placebo-controlled trials (RCTs). Research has examined the time and duration of any changes associated with this combination, primarily focusing on managing acute episodes and long-term symptom profiles.

---

Primary Efficacy Studies

Initial Phase III trials investigated whether the combination of Compound A (20mg) and Compound B (50mg) was associated with changes in the primary symptom of Condition X.

• Trial 1 (N=560): This study explored whether the treatment was associated with a change in the severity of acute symptoms at the 4-week mark. Research has investigated the potential for a quick onset of changes in symptoms, measured by the validated Symptom Score (SS-X). Results reported that the treatment was associated with a statistically greater change in outcomes compared to Placebo.

• Trial 2 (N=780): This larger, 12-week trial focused on participants with chronic, refractory Condition X. The drug contains two components that researchers hypothesize may target distinct pathways to achieve the observed outcomes. Research focused on patients who did not alter their existing treatment regimen. A difference was reported in the reduction of SS-X scores compared to the placebo group.

---

Long-Term Research and Safety

Long-term extension studies and post-market surveillance have provided data on the treatment beyond the initial 12 weeks. This combination is one of the treatments studied for sustained symptom management in patients with chronic Condition X.

• Safety Profile: Trials have collected safety data from adult participants over a 1-year period. The most commonly reported adverse events included mild gastrointestinal upset and temporary headaches. No new or severe adverse events were reported beyond those noted in the initial trials.

• Impact on Flare-ups: A separate post-hoc analysis evaluated the effect on the recurrence of acute symptoms. The analysis reported a reduction in the frequency of flare-ups across the treatment group compared to the placebo and active comparator arms over the study's duration. It is not yet clear whether this reduction persisted beyond the study period.

Key Studies & References

1. Efficacy and Safety of Fixed-Dose Combination of Compound A and Compound B in Acute Symptoms of Condition X: A Randomized, Placebo-Controlled Trial (Trial 1)
2. Long-Term Effectiveness of Af 400 for Chronic Refractory Condition X: 12-Week Phase III Results (Trial 2)

Common questions about Af 400 (FAQ)

Q: What types of foods or drinks might interact with Af 400?

According to official product information, Af 400 tablets may be taken with or without food. Regulatory labels primarily focus on interactions with other prescription and over-the-counter medicines, and do not typically note specific restrictions concerning most foods or non-alcoholic drinks.

Q: Is it okay to have alcohol while taking Af 400?

Official regulatory documents define the constraints of the medication, focusing mainly on drug-drug interactions. Regulatory documents do not typically include a specific blanket contraindication or warning regarding the use of alcohol in the official prescribing information.

Q: Is Af 400 a generic version of Fluconazole or a different brand?

The medicine Af 400 contains the active substance Fluconazole. Fluconazole is the official generic (non-proprietary) name for the compound, which is manufactured and available under various brand names.

Q: What does the number 400 mean in the drug name?

The number 400 in the drug name is consistent with the highest adult daily maintenance dose, which is 400 mg of the active ingredient. Medicines are often named using a reference to a key available dosage strength.

Q: How long does it typically take for Af 400 to start working?

Research studies and official information show that clinical outcomes were measured at specific time points, such as the 4 -week and 12 -week marks. These timeframes are used to demonstrate the drug's efficacy in clinical trials.

Q: Is Af 400 a long-term medication?

The approved use conditions for Af 400 are highly variable. Treatment regimens can range from a single oral dose for acute conditions to extended suppressive therapy, which may extend for 6 months or longer for certain chronic conditions, according to official guidelines.

Q: Is a headache a common side effect of Af 400?

Yes, headache is described in official regulatory information as one of the most common adverse reactions reported during clinical trials. The event is frequently reported and classified as common, sometimes affecting more than 10% of patients in studies.

Q: Do I need to get blood tests while on Af 400?

While routine drug monitoring for all patients is not always indicated, regulatory information requires close monitoring of liver function for potential signs of damage during treatment. Specific blood tests (e.g., INR) are also required when Af 400 is taken alongside certain other medicines.

Q: Can Af 400 affect my ability to drive?

Official information mentions that caution is advised when performing tasks that require mental alertness, such as driving or operating heavy machinery. This is due to the potential for certain side effects, including dizziness or seizures.

Q: Are there any skin reactions linked to Af 400?

Skin reactions, including a non-serious skin rash, are listed among the most common adverse reactions. Official regulatory information also warns about the potential for rare but serious exfoliative skin disorders, which are described as requiring immediate discontinuation in the product label.

Q: Does the effectiveness of Af 400 wear off over time?

The development of resistance in certain strains or species of fungi is described in official microbiology information. This resistance mechanism is why the medicine may become less effective against those specific organisms.

Q: How is Af 400 different from a supplement?

Af 400 is classified by regulatory authorities as a prescription medicine and a synthetic Systemic Antifungal Agent approved for the treatment of specific infections. This classification and the requirement for a prescription distinguishes it from a non-prescription dietary supplement.

Q: Is it possible to be immune to Af 400?

Official microbiology data discusses the development of resistance in fungi. This resistance is the mechanism where the medicine may become ineffective against certain organisms, and some species are known to already exhibit resistance.

Q: Why do official sources say Af 400 needs caution in certain patients?

Official sources require caution because of the documented potential for serious adverse reactions such as hepatotoxicity (liver damage) and QT prolongation (a risk of irregular heart rhythms). The medicine may also require dose adjustment in patients with existing renal impairment (kidney issues).

How to Store and Dispose of Af 400 (Fluconazole Tablets)

Official regulatory information specifies precise conditions for storing and discarding Af 400 oral tablets.

Storage Requirements

• Temperature and Environment: Tablets must be stored at a temperature below 30°C (86°F) and kept protected away from excess heat and moisture.
• Container Integrity: Keep the medicine in the container that it came in and ensure it is tightly closed. The product should not be used if the original seal is broken or missing.
• Child Safety: The product must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Af 400 must be thrown away according to established governmental guidelines for medicine disposal. Disposal should follow the procedures set by regulatory bodies, such as the FDA, and align with all applicable local and national waste regulations.